Anteris Technologies Ltd. and v2vmedtech, inc. announced they have reached concept lock on the first phase of the system. TEER is fast becoming the primary intervention for patients with mitral and tricuspid valve disease, however current marketed systems have limitations that often prevent optimal procedural outcomes or limit eligibility for certain patient groups. The VClipTM design intent is to address these unmet needs and provide better outcomes for patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18 AUD | -1.91% |
|
-1.10% | -6.01% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.01% | 235M | |
-6.24% | 180B | |
-6.08% | 99.21B | |
-5.98% | 66.25B | |
-9.35% | 44.74B | |
+8.34% | 43.82B | |
+10.35% | 41.96B | |
+11.88% | 28.98B | |
+16.18% | 24.07B | |
-8.38% | 23.5B |
- Stock Market
- Equities
- AVR Stock
- News Anteris Technologies Ltd
- Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study